Battolla Enrico, Canessa Pier Aldo, Ferro Paola, Franceschini Maria Cristiana, Fontana Vincenzo, Dessanti Paolo, Pinelli Valentina, Morabito Anna, Fedeli Franco, Pistillo Maria Pia, Roncella Silvio
Division of Clinical Pathology, Azienda Sanitaria Locale n°5, La Spezia, Italy.
Division of Pneumology, Azienda Sanitaria Locale n°5, La Spezia, Italy.
Anticancer Res. 2017 Mar;37(3):1387-1391. doi: 10.21873/anticanres.11460.
In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelin-related peptide (SMRP) in a cohort of Italian patients.
FBLN3 and SMRP were detected in PE from 33 patients with MPM, 64 with pleural benign lesions and 23 with non-MPM pleural metastases using a commercial enzyme-linked-immunosorbent(ELISA)-assay kit according to manufacturers' instructions.
Levels of FBLN3 were similar in PE from MPM and PE from other pathologies (geometric mean=68.1 vs. 66.2 ng/ml; p=0.872) in contrast to SMRP levels, which were significantly higher in PE from MPM (geometric mean=14.6 vs. 3.2 nM; p<0.001). Receiver operating characteristic analysis confirmed that SMRP showed a good performance (area under the curve=0.79, p<0.001), whereas FBLN3 was not able to discriminate MPM from other pathologies (area under the curve=0.44, p=0.838).
FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.
在文献中,关于纤维连接蛋白-3(FBLN3)在恶性胸膜间皮瘤(MPM)中诊断胸腔积液(PE)的价值存在相互矛盾的数据。因此,我们在一组意大利患者中比较了FBLN3与可溶性间皮素相关肽(SMRP)的诊断性能。
根据制造商的说明,使用商用酶联免疫吸附(ELISA)检测试剂盒,在33例MPM患者、64例胸膜良性病变患者和23例非MPM胸膜转移患者的胸腔积液中检测FBLN3和SMRP。
与SMRP水平相反,MPM患者胸腔积液中的FBLN3水平与其他病理类型的胸腔积液中的FBLN3水平相似(几何平均值分别为68.1和66.2 ng/ml;p = 0.872),而MPM患者胸腔积液中的SMRP水平显著更高(几何平均值分别为14.6和3.2 nM;p < 0.001)。受试者工作特征分析证实,SMRP表现良好(曲线下面积 = 0.79,p < 0.001),而FBLN3无法区分MPM与其他病理类型(曲线下面积 = 0.44,p = 0.838)。
与SMRP检测相比,检测胸腔积液中的FBLN3作为MPM所致胸腔积液诊断的生物标志物并无用处。